TCGX is taking its biotech investing playbook into Asia with a new $600 million vehicle aimed at companies across the region. The California-based firm said the TCGX Asia Life Sciences Fund I will invest in Asian biotechs at various stages of development while operating separately from, but in close synergy with, its Western funds.
The launch matters less as a single fundraising event than as a signal about where specialist healthcare capital sees durable deal flow. TCGX is not entering Asia as a first-time life sciences investor: it is transplanting a model it has already used in the West after raising $824 million for its first fund in 2021 and bringing its total haul across two later investment vehicles to $3.1 billion.
Why Asia, why now
TCGX framed the region as a growing source of globally competitive biotech innovation, with China specifically described in the source as part of a blossoming drug discovery base. Managing partner Chen Yu said Asia has become an increasingly important source of biotechnology innovation and that the firm sees an opportunity to work with entrepreneurs and scientists building companies capable of developing medicines for patients worldwide.
That global framing is important. The strategy is not presented as a local market-only bet, but as an effort to find companies in Asia that can scale into broader drug development and financing pathways. For investors, that suggests continued interest in assets that can move across geographies, not just capital staying inside domestic ecosystems.
Building the local platform
TCGX is pairing the fund with an operating expansion, opening offices in Shanghai and Hong Kong. Dandan Dong, who was chief business officer at ArriVent Biopharma before joining TCGX in 2024, will oversee the activities as managing partner of TCGX in Asia.
Dong said the goal is to partner with the most promising biotechs in the region and use the firm's experience, expertise and network to help them realize their potential on a global scale. For portfolio companies, that pitch appears to rest on more than capital alone: TCGX is selling access to financing experience and exit pathways it says it has already demonstrated in Western biotech.
The Western track record behind the pitch
TCGX pointed to several portfolio outcomes as evidence. In late 2023, Roche bought Carmot Therapeutics for $2.7 billion and Bristol Myers Squibb bought RayzeBio for $4.1 billion within a few weeks of each other. Last year, Novartis bought Tourmaline Bio, another TCGX portfolio company, for $1.4 billion.
The firm also highlighted public-market execution. ADARx Pharmaceuticals went public last month, raising $446 million about three years after TCGX co-led a $200 million investment in the siRNA company.
Taken together, the Asia fund suggests specialist investors still see room to back earlier and midstage biotech creation in the region even after a tougher financing cycle. The differentiator now is likely to be whether firms can combine local sourcing with cross-border company building, because that is the capability TCGX is explicitly exporting.
